study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
MUSC-MSK11-01,2012,randomized controlled trial,SMD,0.3696,0.208,0.5312,88,96,low,10.1234/musc-msk11-01,musculoskeletal-journal-01,muscle_recovery,Adults with muscle recovery concerns,Transient headache,8
MUSC-MSK11-02,2017,randomized controlled trial,SMD,0.3642,0.2202,0.5082,71,81,low,10.1234/musc-msk11-02,musculoskeletal-journal-02,muscle_recovery,Adults with muscle recovery concerns,Mild GI discomfort,13
MUSC-MSK11-03,2022,randomized controlled trial,SMD,0.3588,0.2324,0.4852,84,95,some concerns,10.1234/musc-msk11-03,musculoskeletal-journal-03,muscle_recovery,Adults with muscle recovery concerns,None reported,12
